The Chan Zuckerberg Initiative funds several projects within the Human Cell Atlas
Reaching out to comprehensively chart the composition of the human body, the Human Cell Atlas project conducts cellular phenotyping on single-cell level. RNA sequencing methods are at the forefront to inform about cell types and states. However, there are large differences between single-cell RNA...
Coordinator: Holger Heyn (CNAG-CRG, Spain)
European Joint Programme on Rare Diseases
The European Joint Programme on Rare Diseases brings over 130 institutions from 35 countries: 27 EU Member States (Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Croatia, Ireland, Italy, Netherlands, Latvia, Lithuania, Malta, Poland,...
Coordinator: Daria Julkowska (Inserm, France)
Proyecto Genoma 1000 Navarra
NAGEN: Proyecto Genoma 1000 Navarra (NAGEN 1000) is an initiative led by the Navarrabiomed biomedical research centre whose purpose is to transfer the use of the cutting-edge whole human genome analysis technology to Navarra’s public health care system. To this end, 1,000 genomes of patients with...
Coordinator: Ángel Alonso (Navarrabiomed. Spain)
Training the next generation of researchers
ChromDesign is an innovative and interdisciplinary network of 10 European academic and private institutions. Our aim is to characterise how 3D chromatin organisation affects gene regulation during cellular differentiation and in several human disorders. ChromDesign’s main focus is to investigate...
Coordinator: Luciano Di Croce (CRG, Spain)
Solving the unsolved Rare Diseases
Patients with a rare disease generally go through a long and arduous process, sometimes lasting ten or fifteen years (also known as the rare disease odyssey), before finding a physician who knows what is wrong with them. Scientific advances can also take a long time, as it is difficult to find...
Coordinator: Olaf Riess, Holm Graessner (Tübingen, Germany)
Personalised Medicine in Cancer - Catalunya: A pilot study on the impact of genomic testing in the decision-making process in Oncology (PERIS 2016-2020)
Knowledge of the molecular mechanisms of cancer, the new DNA sequencing technologies and the expansion of new therapies aimed at specific targets are key elements for developing a personalised medicine (PM) based on genomics. The best results obtained with personalized oncological therapies justify...
Coordinator: Elias Campo (IDIBAPS, Spain)

Pages